Study of Photobiomodulation Effect on Electroretinogram Outcomes in Dry Age-Related Macular Degeneration

NCT ID: NCT04522999

Last Updated: 2021-09-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-20
• Study Completion Date: 2021-08-13

Brief Summary

To evaluate the ability of Photobiomodulation (PBM) treatment using the Valeda® Light Delivery System to improve Electroretinogram (ERG) outcomes in subjects with dry Age-related Macular Degeneration (AMD).

Detailed Description

This study is an open label, prospective pilot study to evaluate retinal function after PBM treatment in eyes with dry AMD using ERG. The target enrollment is 15 subjects in up to two sites in the US. All subjects will receive PBM Treatment.

Subjects will receive three PBM treatments per week for three weeks for a total of nine sessions over 3 weeks.

The primary analysis will examine multi-focal ERG function changes from baseline to Month 1. Secondary analyses will examine multi-focal ERG function change from baseline to Month 3 and 6. Other endpoints will include other functions of ERG, ETDRS Visual Acuity, Contrast Sensitivity, Perimetry, Color Vision test and the Amsler grid test.

Conditions

Age Related Macular Degeneration

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Photobiomodulation

Valeda™ Light Delivery System

Group Type: EXPERIMENTAL

Photobiomodulation

Intervention Type: DEVICE

The Valeda™ Light Delivery System

Interventions

Photobiomodulation

The Valeda™ Light Delivery System

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Male or female at least 50 years of age at Screening visit
• ETDRS BCVA letter score of between 50* and 75* (Snellen equivalent of 20/100 to 20/32)
• Diagnosis of dry AMD
• Able to communicate well with the Investigator and able to understand and comply with the requirements of the study
• Informed of the nature of this study and has provided written, informed consent in accordance with institutional, local and national regulatory guidelines

Exclusion Criteria

• Current or history of neovascular maculopathy
• Presence of center involving GA within the central ETDRS 1 mm diameter at Screening
• Media opacities, including cataracts, which might interfere with visual acuity or imaging in the study eye(s)
• Posterior capsule opacification, which might interfere with visual acuity or imaging in the study eye(s)
• Invasive eye surgery (e.g. cataract, capsulotomy) on a qualifying eye within three 3 months prior to Screening
• Visually significant disease in any ocular structure apart from dry AMD
• Serious medical illness that will prevent the subject from performing study activities
• Presence of or history of malignancy within the past 5 years
• Presence or history of known light sensitivity to yellow light, red light, or near infrared radiation (NIR), or if they have a history of light activated CNS disorders (e.g. epilepsy, migraine)
• History of neurologic condition known to affect visual function
• History of drug, alcohol or substance abuse within 3 months prior to Screening
• Participation in any other clinical study at time of screening, or has received an investigational drug or treatment with an investigational device within 3 months prior to Screening
• In the opinion of the Investigator, is unlikely to comply with the study protocol

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LumiThera, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Perich Eye Center

New Port Richey, Florida, United States

Countries

United States

Other Identifiers

CSP007

Identifier Type: -

Identifier Source: org_study_id